Upstream Bio FY2028 EPS Estimate Reduced by HC Wainwright

Upstream Bio, Inc. (NASDAQ:UPB) – Equities research analysts at HC Wainwright lowered their FY2028 EPS estimates for Upstream Bio in a research note issued to investors on Wednesday, September 2nd. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($3.17) for the year, down from their previous forecast of ($3.13). HC Wainwright has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for Upstream Bio’s current full-year earnings is ($2.86) per share. HC Wainwright also issued estimates for Upstream Bio’s FY2029 earnings at ($3.64) EPS and FY2030 earnings at ($3.70) EPS.

UPB has been the subject of several other research reports. Truist Financial cut their price objective on shares of Upstream Bio to $25.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. Wall Street Zen cut shares of Upstream Bio from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Mizuho cut their price target on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, May 14th. Weiss Ratings upgraded shares of Upstream Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 17th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Upstream Bio from $8.00 to $9.00 and gave the company a “neutral” rating in a research note on Friday, August 14th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Upstream Bio has an average rating of “Hold” and an average target price of $29.67.

Upstream Bio Stock Down 6.2%

UPB stock opened at $6.08 on Friday. The company has a market cap of $333.00 million, a PE ratio of -2.10 and a beta of 1.28. The business has a 50-day simple moving average of $6.96 and a 200 day simple moving average of $7.91. Upstream Bio has a 52 week low of $5.77 and a 52 week high of $33.68.

Upstream Bio (NASDAQ:UPB) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.01. The firm had revenue of $0.77 million during the quarter, compared to the consensus estimate of $0.56 million. Upstream Bio had a negative net margin of 4,955.67% and a negative return on equity of 48.40%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. California State Teachers Retirement System raised its stake in Upstream Bio by 574.1% during the second quarter. California State Teachers Retirement System now owns 267,347 shares of the company’s stock worth $1,850,000 after acquiring an additional 227,686 shares in the last quarter. Stonepine Capital Management LLC bought a new position in shares of Upstream Bio in the second quarter worth about $231,349. Public Employees Retirement System of Ohio acquired a new stake in shares of Upstream Bio in the 2nd quarter valued at approximately $33,000. Bank of America Corp DE acquired a new stake in shares of Upstream Bio in the 2nd quarter valued at approximately $2,711,000. Finally, Man Group plc bought a new stake in shares of Upstream Bio during the 2nd quarter valued at approximately $511,000.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.